Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001295095 | SCV001484006 | uncertain significance | Bardet-Biedl syndrome | 2024-01-17 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 325 of the TRIM32 protein (p.Met325Val). This variant is present in population databases (rs148027625, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with TRIM32-related conditions. ClinVar contains an entry for this variant (Variation ID: 999138). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002504430 | SCV002812851 | uncertain significance | Sarcotubular myopathy; Bardet-Biedl syndrome 11 | 2021-09-06 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003135919 | SCV003823486 | uncertain significance | not provided | 2019-03-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004749644 | SCV005352251 | uncertain significance | TRIM32-related disorder | 2023-12-27 | no assertion criteria provided | clinical testing | The TRIM32 c.973A>G variant is predicted to result in the amino acid substitution p.Met325Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.028% of alleles in individuals of European (Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |